Pliant Therapeutics 

Yahoo Finance • 13 days ago

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months Data highlighted in oral presentation at AACR’s Clinical Trials Mini Symposium Phase 1b indicat... Full story

Yahoo Finance • 5 months ago

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months Company to accelerate d... Full story

Yahoo Finance • 5 months ago

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its particip... Full story

Yahoo Finance • 5 months ago

Idiopathic Pulmonary Fibrosis Research Report 2025-2035: Market Led by Roche, Pliant Therapeutics, Bristol-Myers Squibb, and Vicore as Next-Gen Antifibrotics and Targeted Therapies Drive Innovation

Company Logo Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease marked by gradual scarring, limiting lung function. The exact cause is unknown, but it combines genetic and environmental factors. With symptoms like shortness... Full story

Yahoo Finance • 6 months ago

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc... Full story

Yahoo Finance • 7 months ago

Align downgraded, NetEase upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: JPMorgan upgraded NetEase (NTES) to Ov... Full story

Yahoo Finance • 9 months ago

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, Calif., Aug. 07... Full story

Yahoo Finance • 10 months ago

Pliant ends development of idiopathic pulmonary fibrosis asset bexotegrast

[End of the road - street sign concept] gguy44 * Pliant Therapeutics is ending development of idiopathic pulmonary fibrosis candidate bexotegrast following poor phase 2b/3 results. * In March, the company ended [https://seekingalpha.c... Full story

Yahoo Finance • 10 months ago

Pliant Therapeutics Provides Update on BEACON-IPF

Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Plia... Full story

Yahoo Finance • 11 months ago

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American... Full story

Yahoo Finance • last year

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at ne... Full story

Yahoo Finance • last year

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX).  Such investors are advised to contact Danielle Peyton at n... Full story

Yahoo Finance • last year

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic Society (ATS) Internat... Full story

Yahoo Finance • last year

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Plia... Full story

Yahoo Finance • last year

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Plia... Full story

Yahoo Finance • last year

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the “Rights Agr... Full story

Yahoo Finance • last year

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board... Full story

Yahoo Finance • last year

Pliant Therapeutics, Inc. Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Pliant Therapeutics, Inc. (“Pliant Therapeutics, Inc.” or “the Compan... Full story

Yahoo Finance • last year

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE... Full story

Yahoo Finance • last year

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate of 275,000 shares of common stock upon v... Full story